What next for the treatment of Psoriasis in Europe?
Research Director Laurent Chanroux investigates the changing market dynamics in Psoriasis in Europe.
Over the last decade, systemic biologic therapies for Psoriasis (PsO) have become widespread and the development of biological therapies has revolutionized the treatment of the disease. A chronic autoimmune disease, psoriasis has an estimated prevalence of 2.5% in Europe, representing approximately 15 million people, with 20–25% of these suffering from severe disease.
Biosimilars: Bringing patients into the conversation
Published in eyeforpharma January 2017 by Mariel Metcalfe
In a recent white paper, we explored the impact that biosimilars are having and likely to have on the rising cost of RA treatment. We looked at physician attitudes to biosimilars and the challenges manufacturers face in gaining widespread acceptance.
What next for biosimilars?
Biosimilar medicines appear to present a significant opportunity to introduce cutting-edge therapies to the treatment landscape for many diseases, while also addressing the cost-effectiveness demands now being made on global healthcare systems. However, these drugs aren’t cheap or easy to manufacture and come with considerable marketing challenges.
Join market research consultants Laurent Chanroux and Richard Head for this complimentary webinar in which they will explore and compare biosimilars in RA and diabetes.
Are biosimilars the answer to the rising cost of RA treatment?
Our latest Free Thinking white paper explores why the uptake of Biosimilars has been slower than expected and asks what's next for RA?
Monoclonal-antibody (mAb) biologics have significantly improved treatment options and outcomes in rheumatoid arthritis (RA), particularly where patients do not respond to conventional disease-modifying anti-rheumatics.
The burden of disease from RA, including the cost of treatment, additional care and loss of productivity, is considerable. With disease onset peaking at 55 to 64 years, this burden will increase as populations age worldwide, aggravated by rising obesity and other characteristics of unhealthy lifestyles. Therapeutic mAbs, are helping to ease that load. As with most biologics, however, they come at a substantial cost.
In a past Free Thinking paper, we looked at the opportunity and challenges for biosimilar mAbs entering the rheumatoid arthritis market. A few years later and according to our Therapy Watch patient record data, uptake of biosimilars remains relatively muted, with marked inconsistencies across the major European markets. With Enbrel biosimilar Benepali about to launch across EU, we ask what’s next for RA?
Biosimilars 2015: Do our research findings suggest a step change in the market?
Q1 2015 has seen big changes for the biosimilar market, and with regulatory pathways now developed almost across the world we can see that biosimilars are becoming more widely accepted.
Laurent Chanroux, Research Director of Therapy Watch, looks at what has happened in 2015 to date and investigates how changes in the RA landscape are impacting rheumatologists’ likelihood to prescribe a biosimilar, using data taken from our Therapy Watch RA patient research study.